SOR C13

Drug Profile

SOR C13

Alternative Names: SOR-C13

Latest Information Update: 29 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Soricimed Biopharma
  • Class Antineoplastics; Peptides
  • Mechanism of Action TRPV6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ovarian cancer; Solid tumours

Most Recent Events

  • 27 Sep 2016 SOR C13 receives Orphan Drug status for Pancreatic cancer in USA
  • 19 Jul 2016 Final adverse events and efficacy data from a phase I trial in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 08 Mar 2016 SOR C13 receives Orphan Drug status for Ovarian cancer (Late-stage disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top